1 / 34

Plant and Mammalian Tissue Culture

Plant and Mammalian Tissue Culture. Introduction to bioprocessing and pharmacutical biotechnology of plant and animal cell culture. Industrial Application of Cell Culture Technology. Large Scale-Up of cell culture Bioprocessing Pharmacutical Biotechnology Industrial Production

cameo
Download Presentation

Plant and Mammalian Tissue Culture

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Plant and Mammalian Tissue Culture Introduction to bioprocessing and pharmacutical biotechnology of plant and animal cell culture

  2. Industrial Application of Cell Culture Technology • Large Scale-Up of cell culture • Bioprocessing • Pharmacutical Biotechnology • Industrial Production • Production of cell material, protein, phytochemicals and other molecules from cell culture • Market – 1 billion upstream processing industry with 5,800 employees • Follow-on biologic or “biosimilar” market is going to grow • Refer to products marketed after expiration of patents • Product can only be made that is similar not identical due to complexity of biologics • Investment and market is driven by a number of successful therapeutic proteins going off-patent between 2013 and 2017 • European and Asian guidelines and competition is an unknown impact

  3. Examples of Bioprocess • Cell Culture and Fermentation Process • Therapeutic Antibody Products • Treat lymphoma, inhibit transplant rejection, anti-metastatic breast cancer, rheumatoid arthritis • Growth Factors (HGH, PDGR, Insulin) • Veterinarian Vaccines – Diarrhea, parvovirus, distemper • Many metabolites – alcohols, citric acid, amino acids • Antibiotics • Blockbuster Proteins • Remicade – monoclonal antibody against TNF-a. • Used to treat Rheumatoid arthritis and Chron’s disease • License approved August 1998 • Possible mechanism of action is inhibiting cytokine receptor activation • $900 for a 100 mg dose! Responsible for $2.1 billion in sales 2009 • Produced in 1,000 liter production reactors

  4. Examples of Manufacturing Plants • Genentech New Vacaville • Started construction in 2004, FDA approval 2009 • $800 million invested • Eight 25,000 liter bioreactors • Production of Herceptin, Avastin and Rituxan • Bristol Myer Squibb • Started construction 2007 – validation I 2011 • $750 million invested • Six 20,000 liter bioreactor, one purification strain • Productioin of Orencia and other biologics

  5. Non-Mammalian Examples • Insect Cell Culture – Baculovirus • 25 compounds in clinical trials • Possible combitorial proteomic approach could lead to more effective protein therapeutics • Yeast – Pichia expression systems. • Need to humanize the glycoprotein expression • Immune system keys in on different “sugared” proteins • Glycofi(Merk) is creating a multistep genetic engineering process to eliminate non-human glycosylation enzymes • Working to batch processing of uniformly glycosylated products • Plant – alfalfa, barley, corn, rice and duckweek have been given field trials • “Edible vaccines” and plant-made pharmacuticals • No current PMP product on market – first will likely be animal health vaccine “Concert”

  6. Production Workflow

  7. Process Optimization** Scale Up Clone Evaluation Media Development* After discovery comes development, lots and lots of it! Expression SystemDevelopment • Knowing gene for the protein you want is great, but what cell line to use? What clone form that cell line is best. 100s of possibilities! • 60 or more nutritional components in culture media, how many combinations? When to feed them? Inducers, promoters? • What temperature? What oxygen level? CO2? pH any shifts? When to harvest? • A strategy of multi-factorial design is the natural way to attack this type of problem, but is difficult to execute in cell culture because the parameters interact strongly-requiring a lot of experiments. This means models! Flasks • Identify target, isolate gene, and develop expression system • Screen and select the highest producing and most stable clone • Develop optimal growth and production media for each cell line • Optimize conditions for biomanufacturing process in a “scale-down” version • Scale up process for use in large bioreactors for production of therapeutic

  8. Bioprocessing • Use of biological materials to create a material for medical or scientific purposes • Upstream and downstream processing

  9. Bioprocessing • Use of biological materials to create a material for medical or scientific purposes • Upstream processing – from gene/cell to harvesting off cell culture media or cell biomass • Downstream processing – lysing, isolating and further purification of bioproduct • All sections require validation, quality control and quality assurance

  10. Some High-Throughput Cell Culture System Requirements • Deliver meaningful scalable data • Sustain cells, control temperature, O2, CO2, pH, agitation • Maintain sterility • Monitor cell density, pH, DO, metabolites, product titer • Operate with accuracy and precision and provide control of process parameters comparable to bench top bioreactor systems • Automatic operation with minimal operator supervision • Integration with tools for designing experiments and handling data

  11. Cell Culture Concerns • Mammalian cells • Fragile and shear sensitive – membranes lyse • Suspension culture cells are needed for scale up • Fluidized bed, hollow-fiber and packed-bed do provide some scale up potential • Slow growing compared to bacteria or yeas (24 hour doubling time) • Low production titer • Extended batch times – facilitate potential contamination • Virus removal and or inactivation is required for further processing • Must start with smaller cultures then move up to large 10,000 and 25,000 liter cultures

  12. Scale up issues • Operating issues that affect reactor design • Heat transfer • Foaming • Sterility • Oxygen transfer

  13. Bioreactor • A bioreactor is a system in which a reaction or biological conversation is effected • Different from fermentor • Enzymes – to produce new product (biofuels) • Microorganisms (beer fermentor) • Animal and Plant Cells • Basic Design of Reactor • Control temperature • Maintain and analyze pH • Measure viability of cells • Culture composition • Sugar, protein, carbon substrate • Oxygen • Product and byproduct removal • Clean and Sanitize In Place (CIP/SIP)

  14. Types of Bioreactors • Internal Mechanical Agitation • Most common and highly flexible • Mechanical agitation – paddles • Disperses gas bubbles • Increases times of bubbles (oxygen transfer)

  15. Types of Bioreactors • Internal Mechanical Agitation • Bubble-Column Reactor • Disperse gas through reactor with plates to enhance dispersion and mixing • Low-Sheer – but air / liquid interface produces denaturation and cell lysis • Energy efficient – low power required

  16. Types of Bioreactors • Airlift Loop • Commonly used • Air is fed through sparger ring in center-bottom of draught tube • Air flows up the tube, forming bubbles and exhausts at top • Degassed liquid (now more dense) flows down creating a circulation flow • Larger fermentors and reactors use this style to meet oxygen and cooling needs

  17. Packed Bed Reactors • Used for monolayer (adherent) cell cultures • Initially used glass beads to grow cells then flow media through beads to change media and oxygen • Glass is still used but also macroporus glass beads, ceramic, polyester and polyurethane disks are used as a growth surface • Critical issues include: high surface to volume ration, diffusion through packed bed, bed height vs. shear and pressure effects • Reservoir of media can be external or internal

  18. Packed Bed Reactors • Hollow Fiber Cell Bioreactor

  19. Packed Bed Reactors • Hollow Fiber Cell Bioreactor • Enhance mass transfer • Provide 3D space for cells to grow • Used with hepatocytes as an artificial Liver (Bioartificial Liver – BAL)

  20. Packed Bed Reactors • Fluidized Bed Bioreactor • Cells are immobized – cultured, on small particles which move with the fluid • Large numbers of particles create a large surface area for high rate of heat, nutrient and oxygen transfer • Works best with high viscosity or gaseous substrates or products are used

  21. Bioreactor Operating Modes • Batch – Inoculate culture and allow to cultivate without changing media • Simple and allows for reduced risk of contamination • Lower capital investment and greater flexibility with media adjustments • Slower – must prepare one batch at a time • Small amounts of product are produced • Fed Batch – allows cells to grow to high density. • Use concentrated feedstock • Add in growth limiting nutrient/substrate – not a change in media • Allows for high cell density with higher working time • Must know very specific details on cell cultured used • Continuous

  22. Bioreactor Operating Modes • Batch – Inoculate culture and allow to cultivate without changing media • Fed Batch – allows cells to grow to high density. • Continuous- perpetual feeding process • Culture medium is fed to cells constantly • May be automated and thus less expensive • Less non-productive time spent emptying, filling and sterilizing reactor • Higher risk of contamination • Greater processing costs – more media • Used in high volume production

  23. Regulatory Concerns • Mammalian Production Systems • Potential for Adventitious Virus • Indicate Breach in cGMP Practices Even if Virus Has No Pathogenic Effect in Humans • Likely Source is Raw Material • Potentially Costly Impact --- Equipment and Facility • Antibiotics to Prevent Microbial Contamination, • Not Ideal • Has Been Done for Repeated Mycoplasma Problems • Inactivation / Disposal, Environmental Concerns • What Happens if 10,000L Catastrophic Failure • Safeguards Available to Prevent Back-flow? • Method to Inactivate Prior to Release to Environment

  24. Regulatory Concerns • Living Production System Rather than Synthetic • Importance of Cell Bank • Variability of Living Organisms • Complex Physiology • Balancing Growth vs Production • Spent Culture Medium is Full of Enzymatic Activity • Impurity Profile • Adventitious Agents, a Host for Propagation • Endogenous • Adventitious • Both Theoretical and Demonstrated Concerns

  25. Unique Features of Bioreactor Production • Often Complex Molecules • Post-translational modification may / may not be important to: • Biological activity --- increase or decrease • Purity Profile • Serum Half Life • Immunogenic Nature of the Molecule(s) • Stability • Subsequent Chemical Modification • “Family” of molecules rather than single entity • Differential Toxicity or Clinically Relevant Activity Differences

  26. How to get the cells? Cell Isolation/Harvesting

  27. Heat Transfer • Large masses of cells actively respiration will produce heat • Control of heat by transfer is one of the two main limitations on size of bioreactors • May use internal coils or external water jacket to control temp • Coils can pose problem for contamination but is more effective with higher surface for potential heat transfer • Coils can also adversely affect mixing with additional unwanted turbulence

  28. Foaming • Foam is a natural byproduct – mostly protein bubbles but some lipid • Foam will block and wet filters causing pressure back-up and contamination • Foam must be controlled by chemical dispersing agents (antifoams) • Maintaining 75% volume capacity of reactor allows for foam to be retained within the vessel

  29. Sterility Sterilization in place (SIP)– cleaning of reactor and bed without dismantling reactor or feed tubes Pressurized steam is used for in-place sterilization of probes, valves and seals All crooks, crevices and surfaces are potential contaminants and must be sterilized Sterilization must be verified and validated

  30. Cleaning Cleaning in place (CIP) is performed after each run and before a new run is initiated Highly alkaline detergents, bases and acids are used with copious amounts of water Cleaning solutions are often plumbed into system for automation

More Related